Jim Birchenough
Stock Analyst at Wells Fargo
(2.60)
# 1,963
Out of 4,818 analysts
41
Total ratings
42.86%
Success rate
19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.81 | +145.46% | 2 | Dec 31, 2024 | |
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $2.80 | +7.14% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $39.08 | +79.12% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.14 | +1,773.54% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $12.49 | +284.31% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.27 | +2,506.11% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.35 | +9,529.63% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.60 | +777.74% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $27.39 | +429.39% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $106.15 | -40.65% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $30.92 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $14.28 | +292.16% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $599.21 | +22.49% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $4.75 | +3,689.47% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $4.56 | +623.68% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.81
Upside: +145.46%
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.80
Upside: +7.14%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $39.08
Upside: +79.12%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.14
Upside: +1,773.54%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $12.49
Upside: +284.31%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.27
Upside: +2,506.11%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.35
Upside: +9,529.63%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.60
Upside: +777.74%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $27.39
Upside: +429.39%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $106.15
Upside: -40.65%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $30.92
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $14.28
Upside: +292.16%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $599.21
Upside: +22.49%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $4.75
Upside: +3,689.47%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $4.56
Upside: +623.68%